Therefore, targeting the USP39/ZEB1 axis holds promise as a novel therapeutic approach in MM, presenting a potential avenue for the development of innovative treatment strategies to improve outcomes for MM patients. This evidence concerns the gene USP39 and Miyoshi myopathy.